Sequence: Acetyl-KLULKLULKULKAC(cRGDfC)LKLUG-NH2
| Experiment Id | EXP000641 |
|---|---|
| Paper | Design of cyclic RGD-conjugated Aib-containing amphipathic helical peptides for targeted delivery of |
| Peptide | PII |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 1.0 µM |
| Rna Concentration | 10 nM |
| Mixing Ratio | 100 |
| Formulation Format | electrostatic peptide/siRNA complex |
| Formulation Components | cRGDfC–MAP(Aib) conjugate peptide + siRNA (complex formed by electrostatic interaction) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549; A549-Luc (luciferase-expressing A549) |
| Animal Model | |
| Administration Route | |
| Output Type | reporter knockdown (luciferase) |
| Output Value | No knockdown (relative luciferase ~control) at 24 h post-treatment |
| Output Units | |
| Output Notes | Uptake/CLSM: weak uptake vs PI/PIII in A549 (fluorescence in lysates and confocal). RNAi: no decrease in luciferase at 1.0 µM/10 nM (ratio 100). |
| Toxicity Notes | No significant LDH release reported vs control at 1.0 µM/10 nM (ratio 100). |
| Curation Notes |